摘要
目的:系统评价黄芩汤治疗溃疡性结肠炎(UC)的有效性与安全性。方法:计算机检索Pub Med,The Cochrane Library,Embase,Web of Knowledge,CBM,Wanfang Data,VIP和CNKI数据库,查找关于以黄芩汤为干预措施治疗UC的随机对照试验,检索时限均从建库至2015年1月24日。由两名研究者按照纳入与排除标准独立筛选文献、提取资料并评价质量后,采用Rev Man 5.2软件进行Meta分析。结果:共纳入5个研究,共计309例患者。Meta分析结果显示,与柳氮磺胺吡啶相比,黄芩汤可以明显提高溃疡性结肠炎治疗的治愈率[RR=1.54,95%CI(1.19,2.01),P=0.001],并且能明显降低不良反应发生率;但不能明显提高治疗的总有效率[RR=1.06,95%CI(0.97,1.17),P=0.21],也不能明显降低临床症状腹泻、脓血便、里急后重、腹痛的积分。结论:黄芩汤治疗溃疡性结肠炎疗效在治愈率与降低不良反应方面优于柳氮磺胺吡啶,上述结论尚需开展更多研究予以验证。
Objective： To systematically review the clinical efficacy of Huangqin Tang in patients with ulcerative colitis （UC）. Method： Databases such as PubMed, The Cochrane Library, Embase, Web of Knowledge, CBM, Wan fang Data, VIP and CNKI were searched for the randomized controlled trials about Huangqin Tang as the interventions for ulcerative colitis from database creation to January 24th, 2015. Two reviewers independently screened literature, extracted data and evaluated methodological quality according to the inclusion and exclusion criteria. Then Meta-analysis was conducted using RevMan 5.2 software. Result： A total of 5 studies involving 309 patients were included. The results of Meta-analysis showed that, compared with sulfasalazine, Huangqin Tang can significantly improve the cure rate of ulcerative colitis I RR = 1.54, 95% CI （1. 19, 2.01）, P = 0. 001 ], and significantly reduce the incidence of adverse reactions, but it can not increase the total effective rate of the treatment ERR = 1.06, 95% CI （0.97, 1.17） , P =0.21 ] or reduce the clinical symptom scores of diarrhea, bloody purulent stool, tenesmus and stomachache. Conclusion： Huangqin Tang is batter than sulfasalazine in terms of curative rate and adverse reactions, but it still needs more studies for verification.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2016年第4期213-217,共5页
Chinese Journal of Experimental Traditional Medical Formulae
